This website uses cookies to store information on your computer. Some of these cookies are used for visitor analysis, others are essential to making our site function properly and improve the user experience. By using this site, you consent to the placement of these cookies. Click Accept to consent and dismiss this message or Deny to leave this website. Read our Privacy Statement for more.
Join Mailing List   |   Jobs   |   Print Page   |   Contact Us   |   Sign In   |   Join
News & Press: ISTH News

New Guidance from the SSC on the Management of Cancer-Associated DIC

Thursday, January 8, 2015   (0 Comments)
Posted by: Luke Blount
Share |

The Journal of Thrombosis and Haemostasis (JTH) has accepted the following article on guidance from the Scientific and Standardization Committee (SSC):

Management of Cancer-associated Disseminated Intravascular Coagulation
The pathogenesis of cancer-associated disseminated intravascular coagulation (DIC) is complex and multifactorial. It could present as a spectrum ranging from clinically asymptomatic, but with laboratory markers of coagulation activation, to the extreme cases of therapy-resistant thrombosis or bleeding [1]. In this guidance, we try to address some practical considerations for this clinical scenario. This statement will provide clinicians with guidance on how best to manage DIC in patients with cancer, and offer expert consensus to help decision-making in challenging situations. 

View the accepted article on guidance for this topic from JTH here.

Membership Management Software Powered by YourMembership  ::  Legal